Literature DB >> 11344228

Enhanced activity of the purine nucleotide cycle of the exercising muscle in patients with hyperthyroidism.

H Fukui1, S Taniguchi , Y Ueta, A Yoshida, A Ohtahara, I Hisatome, C Shigemasa.   

Abstract

Myopathy frequently develops in patients with hyperthyroidism, but its precise mechanism is not clearly understood. In this study we focused on the purine nucleotide cycle, which contributes to ATP balance in skeletal muscles. To investigate purine metabolism in muscles, we measured metabolites related to the purine nucleotide cycle using the semiischemic forearm test. We examined the following four groups: patients with untreated thyrotoxic Graves' disease (untreated group), patients with Graves' disease treated with methimazole (treated group), patients in remission (remission group), and healthy volunteers (control group). To trace the glycolytic process, we measured glycolytic metabolites (lactate and pyruvate) as well as purine metabolites (ammonia and hypoxanthine). In the untreated group, the levels of lactate, pyruvate, and ammonia released were remarkably higher than those in the control group. Hypoxanthine release also increased in the untreated group, but the difference among the patient groups was not statistically significant. The accelerated purine catabolism did not improve after 3 months of treatment with methimazole, but it was completely normalized in the remission group. This indicated that long-term maintenance of thyroid function was necessary for purine catabolism to recover. We presume that an unbalanced ATP supply or conversion of muscle fiber type may account for the acceleration of the purine nucleotide cycle under thyrotoxicosis. Such acceleration of the purine nucleotide cycle is thought to be in part a protective mechanism against a rapid collapse of the ATP energy balance in exercising muscles of patients with hyperthyroidism.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11344228     DOI: 10.1210/jcem.86.5.7516

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  6 in total

1.  Gender impact on the correlations between Graves' hyperthyroidism and hyperuricemia in Chinese.

Authors:  Xuehui Liu; Jianping Zhang; Zhaowei Meng; Qiang Jia; Jian Tan; Guizhi Zhang; Xue Li; Na Liu; Tianpeng Hu; Pingping Zhou; Qing Zhang; Kun Song; Qiyu Jia
Journal:  Ir J Med Sci       Date:  2018-11-30       Impact factor: 1.568

Review 2.  The MCT8 thyroid hormone transporter and Allan-Herndon-Dudley syndrome.

Authors:  Charles E Schwartz; Roger E Stevenson
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2007-06       Impact factor: 4.690

3.  Integration of whole-body [18F]FDG PET/MRI with non-targeted metabolomics can provide new insights on tissue-specific insulin resistance in type 2 diabetes.

Authors:  Klev Diamanti; Robin Visvanathar; Maria J Pereira; Marco Cavalli; Gang Pan; Chanchal Kumar; Stanko Skrtic; Ulf Risérus; Jan W Eriksson; Joel Kullberg; Jan Komorowski; Claes Wadelius; Håkan Ahlström
Journal:  Sci Rep       Date:  2020-05-20       Impact factor: 4.379

4.  Thyroid Hormone-Regulated Expression of Period2 Promotes Liver Urate Production.

Authors:  Xiaoting Chen; Mian Wu; Nan Liang; Junxi Lu; Shen Qu; Haibing Chen
Journal:  Front Cell Dev Biol       Date:  2021-04-01

Review 5.  The Association with Subclinical Thyroid Dysfunction and Uric Acid.

Authors:  Yuling Xing; Linlin Yang; Jing Liu; Huijuan Ma
Journal:  Int J Endocrinol       Date:  2021-12-13       Impact factor: 3.257

6.  Myoglobin-Pyruvate Interactions: Binding Thermodynamics, Structure-Function Relationships, and Impact on Oxygen Release Kinetics.

Authors:  Kiran Kumar Adepu; Dipendra Bhandari; Andriy Anishkin; Sean H Adams; Sree V Chintapalli
Journal:  Int J Mol Sci       Date:  2022-08-06       Impact factor: 6.208

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.